{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-028993","form_type":"8-K","ticker":"OCUL","cik":"0001393434","company_name":"OCULAR THERAPEUTIX, INC","filed_at":"2023-03-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.733138+00:00","generated_at":"2026-06-18T11:20:15.637426+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Ocular Therapeutix Q4 DEXTENZA rev $13.9M (+14% YoY); guides 2023 rev $55-60M; net loss $71M","bullets":["DEXTENZA net product revenue Q4 2022 $13.9M (+14% YoY, +17% QoQ); full year $50.5M (+20% YoY).","Total net revenue full year 2022 $51.5M (+18% YoY); net loss $(71.0)M vs $(6.6)M in 2021 (includes $5.2M non-cash item).","Cash and equivalents $102.3M at Dec 31, 2022; company expects cash runway to mid-2024.","OTX-TKI Phase 1 wet AMD: 73% rescue-free at 10 months; 92% reduction in treatment burden; pivotal trial planned Q3 2023.","OTX-TIC Phase 2 glaucoma top-line data expected Q4 2023; Phase 1 diabetic retinopathy trial initiated Dec 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-028993","json":"https://secwatch.observer/filing/0001104659-23-028993.json","markdown":"https://secwatch.observer/filing/0001104659-23-028993.md","text":"https://secwatch.observer/filing/0001104659-23-028993.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923028993/0001104659-23-028993-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923028993/tm238596d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T11:20:15.637426+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5c3d17709fe464457363004a255058b8ecc80a5a","claim":"OCULAR THERAPEUTIX, INC reported the fourth quarter and year ended December 31, 2022 results: revenue $51.5 million.","evidence_excerpt":"intracameral implant) for the Treatment of Patients with Primary Open-Angle Glaucoma or Ocular Hypertension Expected in Q4 2023 Total Net Revenue for Full Year 2022 was $51.5 million, Representing Growth of 18% Over the Prior Year DEXTENZA ® Net Product Revenue in the Fourth Quarter of 2022 was $13.9 million, Representing Growth of approximately 17% Over","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1393434/000110465923028993/0001104659-23-028993-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and year ended December 31, 2022"},{"label":"Revenue","value":"$51.5 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}